| Company Name: |
Nanjing Haolv Biotechnology Co.,Ltd
|
| Tel: |
025-84622273 17361806303 |
| Email: |
3004208264@qq.com |
| Products Intro: |
Product Name:Leflunomide-d4 (phenyl-d4)
CAS:1189987-23-2
Purity:98% Package:5g;25g;100g
|
| Company Name: |
Hefei Molake Biotechnology Co., Ltd.
|
| Tel: |
0551-66336380 18956014586 |
| Email: |
983438788@qq.com |
| Products Intro: |
Product Name:Leflunomide-d4
CAS:1189987-23-2
Purity:98% Package:10mg,100mg,1g,10g
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing1@energy-chemical.com |
| Products Intro: |
Product Name:Leflunomide-d4
CAS:1189987-23-2
Purity:NULL Package:10mg;1mg Remarks:NULL
|
| Company Name: |
ChengDu SinoStandards Bio-Tech Co.,Ltd. ，
|
| Tel: |
028-83243028 19136088901 |
| Email: |
sinostandards@163.com |
| Products Intro: |
Product Name:Leflunomide-d4 (phenyl-d4)
CAS:1189987-23-2
Purity:98 atom % D Package:10mg;100mg;1g
|
| Company Name: |
Yancheng Tongming Biotechnology Co., Ltd.
|
| Tel: |
15195160625 |
| Email: |
2863565288@qq.com |
| Products Intro: |
Product Name:Leflunomide-d4 (phenyl-d4)
CAS:1189987-23-2
Purity:98% HPLC Package:0.005 g In Stock
0.01 g In Stock
|
|
| | 5-methyl-N-[2,3,5,6-tetradeuterio-4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Basic information |
| | 5-methyl-N-[2,3,5,6-tetradeuterio-4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: soluble,Methanol: soluble | | form | A solid |
| | 5-methyl-N-[2,3,5,6-tetradeuterio-4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Usage And Synthesis |
| Uses | An immunosuppressive. Inhibits T and B cell proliferation. Activity is attributed mainly to its metabolite, a malononitrile derivative, which is beleived to inhibit dihydroorotate dehydrogenase as well as several protein tyrosine kinases.This compound is suitable for dihydroorotate dehydrogenase (DHODH) related research. | | Biological Activity | Leflunomide-d4 is intended for use as an internal standard for the quantification of leflunomide by GC- or LC-MS. Leflunomide is a synthetic isoxazol and a prodrug form of A-771726 , a dihydroorotate dehydrogenase inhibitor.1 Leflunomide inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle. It inhibits proliferation and activation of T cells when used at concentrations of 25 and 100 μM, respectively, for na?ve and memory CD4+ T cells.2 It also reduces the production of Th1 effector cells and increases differentiation of Th2 cells in vitro and in splenocytes isolated from KLH-immunized mice. Leflunomide (35 mg/kg per day) reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis.3 Formulations containing leflunomide have been used in the treatment of active rheumatoid arthritis. | | References | 1.Breedveld, F.C., and Dayer, J.-M.Leflunomide: Mode of action in the treatment of rheumatoid arthritisAnn. Rheum. Dis.59(11)841-849(2000)
2.Dimitrova, P., Skapenko, A., Herrmann, M.L., et al.Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiationJ. Immunol.169(6)3392-3399(2002)
3.Glant, T.T., Mikecz, K., Bartlett, R.R., et al.Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomideImmunopharmacology23(2)105-116(1992) |
| | 5-methyl-N-[2,3,5,6-tetradeuterio-4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Preparation Products And Raw materials |
|